Kiora Pharmaceuticals (Kiora Pharmaceuticals) Operating Income : $-8.69 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Operating Income?

Kiora Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-1.99 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.69 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Kiora Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-1.99 Mil. Kiora Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Kiora Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was %.

Kiora Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kiora Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -83.45%. Kiora Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -26,576.74%.

Kiora Pharmaceuticals Operating Income Historical Data

The historical data trend for Kiora Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Operating Income Chart

Kiora Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-7.11

-8.21

-10.67

-11.73

-8.69

Kiora Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Income	Get a 7-Day Free Trial															-3.62	-1.71	-2.49	-2.50	-1.99

Kiora Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.69 Mil.

Kiora Pharmaceuticals (NAS:KPRX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kiora Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-7.968 * ( 1 - 0% )	/	( (9.427	+	9.67)	/ 2 )
=	-7.968	/	9.5485
=	-83.45 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15.896	-	1.587	-	( 5.4	-	max(0, 2.101	-	6.983	+	5.4	))
=	9.427

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13.712	-	1.587	-	( 2.455	-	max(0, 1.634	-	4.738	+	2.455	))
=	9.67

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Kiora Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-22.856	/	( ( (0.057 + max(-1.842, 0))	+	(0.115 + max(-1.354, 0)) )	/	2 )
=	-22.856	/	( ( 0.057	+	0.115 )	/	2 )
=	-22.856	/	0.086
=	-26,576.74 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.24)	-	(1.587	+	0	+	0.495)
=	-1.842

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.233)	-	(1.587	+	0	+	0)
=	-1.354

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Kiora Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.992	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Kiora Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

7EY0:Germany

Address

332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024

Website

https://www.kiorapharma.com

Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.

Executives

Carmine N. Stengone	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca	officer: EVP of Finance	C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler	officer: Interim CFO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
David Hollander	director	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem	director, officer: President and CEO	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels	officer: Chief Development Officer	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro	director	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron	director	75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr	officer: Acting CEO	C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110